ATRA:NSD-Atara Biotherapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 13.94

Change

+0.09 (+0.65)%

Market Cap

USD 1.17B

Volume

1.00M

Average Target Price

USD 29.57 (+112.13%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-0.16 (-0.10%)

USD64.10B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+3.97 (+1.83%)

USD56.20B 21.10 15.27
REGN Regeneron Pharmaceuticals, Inc

+13.48 (+2.80%)

USD51.55B 15.77 12.24
ALXN Alexion Pharmaceuticals, Inc

+2.25 (+1.45%)

USD34.14B 57.09 33.71
BNTX BioNTech SE

+8.12 (+6.12%)

USD31.31B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.16 (+2.38%)

USD27.77B N/A N/A
SGEN Seagen Inc

+5.44 (+3.77%)

USD26.14B 42.79 34.88
RPRX Royalty Pharma plc

-0.47 (-1.12%)

USD25.57B 22.60 15.33
GMAB Genmab A/S

+0.31 (+0.89%)

USD22.68B 26.59 3.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ATRA

Symbol Name Weight Mer Price(Change) Market Cap
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

+0.72 (+1.46%)

USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -28.99% 13% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.99% 13% F 7% F
Trailing 12 Months  
Capital Gain 69.59% 64% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.59% 64% D 54% F
Trailing 5 Years  
Capital Gain -34.37% 42% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.37% 42% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 22.98% 58% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.98% 57% F 73% C
Risk Return Profile  
Volatility (Standard Deviation) 87.62% 31% F 17% F
Risk Adjusted Return 26.23% 54% F 49% F
Market Capitalization 1.17B 74% C 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.51 77% C+ 58% F
Price / Cash Flow Ratio -6.48 44% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -81.43% 34% F 14% F
Return on Invested Capital -82.08% 26% F 10% F
Return on Assets -41.49% 23% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 13.52 5% F 2% F
Short Percent 17.91% 9% F 9% F
Beta 2.45 8% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector